Harmony Biosciences Raises 2026 Revenue Estimate to $1.02B, Cuts EPS to $3.58
Harmony Biosciences will report Q1 2026 results May 7 with expected revenue of $227.27 million and earnings of $0.75 per share. Analysts raised full-year 2026 revenue forecast to $1.02 billion from $1.00 billion while cutting EPS to $3.58 and Q4 revenue beat by 1.41% but EPS slumped 54.55%.
1. Q1 2026 Earnings Preview
Harmony Biosciences is scheduled to release Q1 2026 results on May 7, with consensus forecasts calling for $227.27 million in revenue and $0.75 in earnings per share.
2. Full-Year Estimate Revisions
Over the past 90 days analysts have lifted the 2026 revenue projection from $1.00 billion to $1.02 billion and the 2027 projection from $1.13 billion to $1.16 billion, while cutting full-year EPS forecasts from $4.12 to $3.58 for 2026 and from $4.77 to $4.26 for 2027.
3. Q4 Performance and Analyst Outlook
In Q4 2025 Harmony delivered $243.78 million in revenue, beating estimates by 1.41%, but posted $0.38 in EPS, missing estimates by 54.55%, and saw its stock rise 4.91% the following day. Analyst price targets average $43.00, implying 32.1% upside, while an internal valuation of $57.21 suggests 75.7% potential gain.